Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04464577

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

A Phase 1, Open-label Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Pharmacokinetics and Safety of BMS-986235

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study will evaluate the effect of inhibitors, at steady state, on the drug levels, safety, and tolerability of BMS-986235 when taken by healthy participants. The inhibitors to be utilized in this study are fluconazole, bupropion, and itraconazole.

Conditions

Interventions

TypeNameDescription
DRUGFluconazoleSpecified Dose on Specified Days
DRUGBupropionSpecified Dose on Specified Days
DRUGItraconazoleSpecified Dose on Specified Days
DRUGBMS-986235Specified Dose on Specified Days

Timeline

Start date
2021-04-01
Primary completion
2021-06-07
Completion
2021-06-08
First posted
2020-07-09
Last updated
2022-03-25

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04464577. Inclusion in this directory is not an endorsement.